US20020068360A1 - Cyclohexanediol cryoprotectant compounds - Google Patents

Cyclohexanediol cryoprotectant compounds Download PDF

Info

Publication number
US20020068360A1
US20020068360A1 US09/835,818 US83581801A US2002068360A1 US 20020068360 A1 US20020068360 A1 US 20020068360A1 US 83581801 A US83581801 A US 83581801A US 2002068360 A1 US2002068360 A1 US 2002068360A1
Authority
US
United States
Prior art keywords
cryopreservation composition
cryopreservation
cyclohexanediol
compound
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/835,818
Other languages
English (en)
Inventor
Kelvin Brockbank
Michael Taylor
Lia Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organ Recovery Systems Inc
Original Assignee
Organ Recovery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organ Recovery Systems Inc filed Critical Organ Recovery Systems Inc
Priority to US09/835,818 priority Critical patent/US20020068360A1/en
Assigned to ORGAN RECOVERY SYSTEMS reassignment ORGAN RECOVERY SYSTEMS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BROCKBANK, KELVIN G. M., CAMPBELL, LIA HANSON, TAYLOR, MICHAEL J.
Publication of US20020068360A1 publication Critical patent/US20020068360A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to particular cyclohexanediol molecules and their use as cryoprotectants.
  • Cryobiology may be defined as the study of the effects of temperatures of lower than normal physiologic ranges upon biologic systems.
  • the fundamentals of the science of cryobiology have evolved to the point where low temperatures are now used extensively as a means to protect and preserve biological systems during enforced periods of ischemia and hypoxia.
  • preservation is achieved using either hypothermia without freezing, or cryopreservation in which the aqueous system sustains a physical phase change with the formation of ice.
  • survival of cells from the rigors of freezing and thawing in cryopreservation procedures is only attained by using appropriate cryoprotective agents (CPAs) and in general, these techniques are applicable to isolated cells in suspension or small aggregates of cells in simple tissues. More complex tissues and organs having a defined architecture are not easily preserved using conventional cryopreservation techniques, which is principally due to the deleterious effects of ice formation in an organized multicellular tissue. Simply freezing cells or tissues results in dead, nonfunctional materials.
  • cryobiology A basic principle of cryobiology is that the extent of freezing damage depends upon the amount of free water in the system and the ability of that water to crystallize during freezing. Many types of isolated cells and small aggregates of cells can be frozen simply by following published procedures, but obtaining reproducible results for more complex tissues requires an understanding of the major variables involved in tissue cryopreservation.
  • Major variables involved in tissue freezing include (1) freezing-compatible pH buffers, (2) cryoprotectant choice, concentration and administration, (3) cooling protocol, (4) storage temperature, (5) warming protocol and (6) cryoprotectant elution.
  • cryoprotectants have been discovered. See, for example, Brockbank, supra. Cryoprotectant selection for cryopreservation is usually restricted to those that confer cryoprotection in a variety of biological systems. On occasion, combinations of cryoprotectants may result in additive or synergistic enhancement of cell survival. Comparison of chemicals with cryoprotectant properties reveals no common structural features. These chemicals are usually divided into two classes: (1) intracellular cryoprotectants with low molecular weights that penetrate cells, and (2) extracellular cryoprotectants with relatively high molecular weights (greater than or equal to sucrose (342 daltons)) which do not penetrate cells.
  • Intracellular cryoprotectants such as glycerol and dimethyl sulfoxide at concentrations from 0.5 to 3 molar, are effective in minimizing cell damage in many slowly frozen biological systems.
  • Extracellular cryoprotective agents such as polyvinylpyrrolidone or hydroxyethyl starch are often more effective at protecting biological systems cooled at rapid rates.
  • AFPs naturally occurring anti-freeze proteins
  • the present invention relates to the use of newly discovered cryoprotectant compounds.
  • the invention relates to the use of cyclohexanediol compounds, specifically the cis or trans forms of 1,3-cyclohexanediol (1,3CHD) and 1,4-cyclohexanediol (1,4CHD), and their racemic mixtures, as cryoprotectants in preserving living cells.
  • cells to be cryopreserved are protected against the effects of cryopreservation by bringing the cells into contact with a cryopreservation composition containing at least one cyclohexanediol compound, and subsequently reducing the temperature of the cells to the cryopreservation temperature.
  • the cryopreservation composition preferably comprises not only at least one cyclohexanediol compound, but also at least one additional cryoprotectant compound and/or at least one anti-freeze protein.
  • FIG. 1 is a flow chart summarizing the cryopreservation procedure utilized in obtaining the results summarized in this application.
  • FIGS. 2 - 3 are plots of relative cell viability after freezing using CHD compounds in conjunction with conventional cryoprotective agents.
  • FIGS. 4 - 5 are plots of relative cell viability after freezing using CHD compounds in conjunction with anti-freeze proteins.
  • the inventors have discovered two new compounds exhibiting cryoprotective activity, 1,3-cyclohexanediol (1,3CHD) and 1,4-cyclohexanediol (1,3CHD).
  • the inventors have also discovered that these compounds are able to work in conjunction with naturally occurring anti-freeze proteins (AFPs) to promote survival after freezing in a cumulative manner.
  • AFPs anti-freeze proteins
  • Cryopreservation i.e., the preservation of cells by freezing
  • freezing as used herein is meant temperatures below the freezing point of water, i.e., below 0° C.
  • Cryopreservation typically involves freezing cells to temperatures well below freezing, for example to ⁇ 130° C. or less.
  • the cryopreservation temperature should be less than ⁇ 20° C., more preferably ⁇ 80° C. or less, most preferably ⁇ 130° C. or less.
  • the cells to be cryopreserved using the CHD cryoprotectant compounds of the invention may be in suspension, may be attached to a substrate, etc., without limitation.
  • the cells to be protected during cryopreservation are first brought into contact with a cryopreservation composition.
  • a cryopreservation composition By being brought into contact with the cryopreservation composition is meant that the cells are made to be in contact in some manner with the cryopreservation composition so that during the reduction of temperature to the cryopreservation temperature, the cells are protected by the cryopreservation composition.
  • the cells may be brought into contact with the cryopreservation composition by filling the appropriate wells of a plate to which the cells to be protected are attached, by suspending the cells in a solution of the cryopreservation composition, etc.
  • the cells to be cryopreserved should also preferably be in contact with freezing compatible pH buffer comprised most typically of at least a basic salt solution, an energy source (for example, glucose) and a buffer capable of maintaining a neutral pH at cooled temperatures.
  • an energy source for example, glucose
  • a buffer capable of maintaining a neutral pH at cooled temperatures include, for example, Dulbecco's Modified Eagle Medium (DMEM). This material may also be included as part of the cryopreservation composition.
  • DMEM Dulbecco's Modified Eagle Medium
  • the cryopreservation composition of the invention must contain at least one cyclohexanediol (CHD) compound, for example the cis or trans forms of 1,3-cyclohexanediol or 1,4-cyclohexanediol and racemic mixtures thereof.
  • the CHD compound is present in the cryopreservation composition in an amount of from, for example, 0.05 to 2.0 M, more preferably from 0.1 M to 1.0 M.
  • the cryopreservation composition also preferably includes a solution well suited for organ storage.
  • the solution can include the buffers discussed above.
  • a particularly preferred solution is, for example, EuroCollins Solution comprised of dextrose, potassium phosphate monobasic and dibasic, sodium bicarbonate and potassium chloride.
  • the cryopreservation composition contains not only the CHD compound, but also at least one additional cryoprotectant compound.
  • additional cryoprotectant compounds may include, for example, any of those set forth in Table 10.1 of Brockbank, supra, including, but not limited to, acetamide, agarose, alginate, 1-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, dextrans, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, ⁇ -glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol,
  • the cryopreservation composition includes the CHD compound, with or without an additional cryoprotectant compound, and also includes an anti-freeze protein/peptide (AFP).
  • AFPs also include anti-freeze glycoproteins (AFGPs) and insect anti-freeze, or “thermal hysteresis” proteins, (THPs).
  • AFGPs anti-freeze glycoproteins
  • THPs thermo hysteresis proteins
  • AFP any of the well-known AFPs may be used in the present invention in this regard. See, for example, Sicheri and Yang, Nature, 375:427-431, (1995), describing eight such proteins. Most preferably, the AFP may be, for example, AFPI (AFP type I), AFPIII (AFP type III) and/or AFGP.
  • AFPI AFP type I
  • AFPIII AFP type III
  • AFGP AFGP
  • the AFPs may be present in the cryopreservation composition in an amount of from, for example, 0.01 to 1 mg/mL, more preferably 0.05 to 0.5 mg/mL, of composition, for each AFP present.
  • the cells may then be frozen for cryopreservation.
  • the cryopreservation and subsequent warming of cells may be conducted in any manner, and may utilize any additional materials, well known in the art. Preferred embodiments are described in the following discussion and the Examples set forth below.
  • the cooling (freezing) protocol for cryopreservation in the present invention may be any suitable type. Many types of cooling protocols are well known to practitioners in the art. Most typically, the cooling protocol calls for continuous rate cooling from the point of ice nucleation to ⁇ 80° C., with the rate of cooling depending on the characteristics of the cells/tissues being frozen as understood in the art (again, see Brockbank, supra). The cooling rate may be, for example, ⁇ 0.1° C. to 10° C. per minute, more preferably between ⁇ 1° C. to ⁇ 2° C. per minute. Once the cells are cooled to about ⁇ 80° C. by this continuous rate cooling, they can be transferred to liquid nitrogen or the vapor phase of liquid nitrogen for further cooling to the cryopreservation temperature, which is below the glass transition temperature of the freezing solution (again, typically ⁇ 130° C. or less).
  • the warming protocol for taking the cells out of the frozen state may be any type of warming protocol, which are well known to practitioners in the art. Typically, the warming is done in a one-step procedure in which the cryopreserved specimen is placed into a water bath (temperature of about 37-42° C.) until complete rewarming is effected. More rapid warming is also known.
  • cryopreserved cells particularly cryopreserved cells fixed to a substrate
  • cryopreserved cells fixed to a substrate are warmed by way of the methods described in co-pending Application No. ______ (Docket No. 106006) filed on even date herewith, entitled “Novel Warming Method of Cryopreserved Specimens,” incorporated herein by reference in its entirety. These methods include a two-step warming protocol, with or without the use of a heat sink.
  • the cryopreservation composition of the present invention that includes at least one CHD compound is surprisingly able to increase the survival of cryopreserved cells upon freezing in a cumulative manner.
  • the following examples illustrate the surprising utility of the CHD compounds as a cryoprotectant.
  • AV5 cells are derived from porcine heart valve leaflets. Hearts were obtained from pigs and the heart valve leaflets were then removed and washed several times with sterile phosphate-buffered saline (PBS). Small pieces ( ⁇ 1 mm 2 ) were cut and placed into a 24-well microtiter plate coated with 0.2% gelatin. Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal calf serum (FCS) was added to just cover the bottom of the well and the plate was left at 37° C. with 5% CO 2 in air until visible outgrowth occurred.
  • DMEM Dulbecco's Modified Eagle's Medium
  • FCS fetal calf serum
  • AV5 cells were plated the day before each experiment at 25,000 cells/well. At the beginning of each experiment, the plate was placed on ice and the cells were exposed to mannitol prior to loading the various cryopreservation compositions.
  • cryopreservation compositions were formulated in EuroCollins Solution, consisting of dextrose, potassium phosphate monobasic and dibasic, sodium bicarbonate and potassium chloride. The plates were then cooled at the rate of ⁇ 1.0° C./min to ⁇ 80° C., and then further cooled with liquid nitrogen vapor and stored overnight at ⁇ 135° C.
  • Alamar Blue is a fluorescent dye that measures the oxidation/reduction reactions within cells, and thus is indicative of the overall viability of the cells after exposure to cryoprotective agents.
  • a volume of 20 ⁇ l Alamar Blue was added to cells in 200 ⁇ l of DMEM (10% FCS) and the plate was incubated at 37° C. for 3 hours. Fluorescence from Alamar Blue was read in a fluorescent microplate reader (Fmax fluorescent microplate reader by Molecular Dynamics) using an excitation wavelength of 544 nm and an emission wavelength of 590 nm.
  • the first set of experiments involved using two CPA compositions either 1 M dimethyl sulfoxide (DMSO) (left bar of graph at each concentration of 1,3CHD in FIG. 2 and 1,4CHD in FIG. 3) or a combination of DMSO, formamide and propanediol at a final concentration of 1 M (right bar of graph at each concentration of 1,3CHD in FIG. 2 and 1,4CHD in FIG. 3).
  • Concentrations varying from 0 to 1 M of 1,3CHD and 0 to 1 M 1,4CHD were added to these two separate CPA compositions for additional experiments. Cell viability was assessed using the assay described above.
  • FIGS. 2 and 3 relate to 1,3CHD
  • FIG. 3 relates to 1,4CHD.
  • the data was normalized to the conventional cryoprotectant alone and is the mean (+/ ⁇ SEM) of 12 replicates.
  • viability was significantly increased over the comparative cryopreservation compositions that contained only the conventional cryoprotectants without a CHD compound (i.e., concentration of 0.00 CHD).
  • an anti-freeze protein was added to the cryoprotective composition.
  • Varying concentrations of three different AFPs AFPI, AFPIII and AFGP
  • 1 M DMSO 0.25 M 1,3CHD (FIG. 5) or 0.5 M 1,4CHD (FIG. 4).
  • AFPI, AFPIII and AFGP 0.25 M 1,3CHD
  • AFGP 0.25 M 1,4CHD
  • FIG. 4 the relative cell viability of AV5 cells after freezing using a combination of 1,4CHD/AFPI/DMSO is summarized. Concentrations of the constituents included 0.5 M 1,4CHD, 0.1 mg/mL AFPI and 1 M DMSO. The graph depicts viability in the presence of 1 M DMSO alone or in combination with 1,4CHD or 1,4CHD plus AFPI at the above concentrations. Data was normalized to the conventional cryoprotectant (DMSO) alone and is the mean (+/ ⁇ SEM) of 3 replicates.
  • DMSO conventional cryoprotectant
  • FIG. 5 the relative cell viability of AV5 cells after freezing using a combination of 1,3CHD, DMSO and three different AFP proteins is summarized. Concentrations of the constituents included 0.25 M 1,3CHD, 1 M DMSO and 0.1 mg/mL for each AFP protein (left bar of graph is with AFPI, middle bar of graph is with AFPIII, and right bar of graph is with AFGP). Data was normalized to the DMSO alone and is the mean (+/ ⁇ SEM) of 3 replicates.
  • AFPI appears to confer the best protection to the cells in this Example as observed by an increase in cell viability as compared to the conventional cryoprotectant alone or to the conventional cryoprotectant/CHD mixture. This cumulative increase in viability is not observed in the presence of the AFPs plus a conventional cryoprotectant alone (i.e., without the CHD present).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Ceramic Products (AREA)
US09/835,818 2000-04-17 2001-04-17 Cyclohexanediol cryoprotectant compounds Abandoned US20020068360A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/835,818 US20020068360A1 (en) 2000-04-17 2001-04-17 Cyclohexanediol cryoprotectant compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19766900P 2000-04-17 2000-04-17
US09/835,818 US20020068360A1 (en) 2000-04-17 2001-04-17 Cyclohexanediol cryoprotectant compounds

Publications (1)

Publication Number Publication Date
US20020068360A1 true US20020068360A1 (en) 2002-06-06

Family

ID=22730293

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/835,818 Abandoned US20020068360A1 (en) 2000-04-17 2001-04-17 Cyclohexanediol cryoprotectant compounds

Country Status (8)

Country Link
US (1) US20020068360A1 (fr)
EP (1) EP1274302B1 (fr)
JP (1) JP2003530406A (fr)
AT (1) ATE270037T1 (fr)
AU (1) AU2001255433A1 (fr)
DE (1) DE60104105T2 (fr)
ES (1) ES2367352T3 (fr)
WO (1) WO2001078505A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100476790B1 (ko) * 2002-09-13 2005-03-16 주식회사 제넨메드 세포 저장 용액과 이를 이용한 동물 세포의 동결 및 저장방법
US20050244692A1 (en) * 2002-11-05 2005-11-03 Hiroshi Egawa Fuel cell coolant composition
US20060145120A1 (en) * 2003-07-11 2006-07-06 Hiroshi Egawa Cooling liquid composition for fuel cell
US20060237686A1 (en) * 2003-10-16 2006-10-26 Hiroshi Egawa Coolant composition
US20070007489A1 (en) * 2003-12-25 2007-01-11 Hiroshi Egawa Heat transfer medium composition
US20070075289A1 (en) * 2004-03-24 2007-04-05 Hiroshi Egawa Coolant composition for fuel cell
US20070096054A1 (en) * 2003-10-01 2007-05-03 Hiroshi Egawa Coolant composition and methods of use thereof
US20090142830A1 (en) * 2005-11-17 2009-06-04 Nippon Zenyaku Kogyo Co., Ltd. Aqueous Solution for Cell Preservation
US8785116B2 (en) 2012-08-10 2014-07-22 Paragonix Technologies, Inc. Methods for evaluating the suitability of an organ for transplant
US8828710B2 (en) 2011-03-15 2014-09-09 Paragonix Technologies, Inc. System for hypothermic transport of samples
US8835158B2 (en) 2011-03-15 2014-09-16 Paragonix Technologics, Inc. Apparatus for oxygenation and perfusion of tissue for organ preservation
US9253976B2 (en) 2011-03-15 2016-02-09 Paragonix Technologies, Inc. Methods and devices for preserving tissues
US9426979B2 (en) 2011-03-15 2016-08-30 Paragonix Technologies, Inc. Apparatus for oxygenation and perfusion of tissue for organ preservation
US9560846B2 (en) 2012-08-10 2017-02-07 Paragonix Technologies, Inc. System for hypothermic transport of biological samples
US9867368B2 (en) 2011-03-15 2018-01-16 Paragonix Technologies, Inc. System for hypothermic transport of samples
USD819223S1 (en) 2014-10-10 2018-05-29 Paragonix Technologies, Inc. Transporter for a tissue transport system
US11166452B2 (en) 2017-06-07 2021-11-09 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
US11178866B2 (en) 2011-03-15 2021-11-23 Paragonix Technologies, Inc. System for hypothermic transport of samples
US11632951B2 (en) 2020-01-31 2023-04-25 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
USD1031028S1 (en) 2022-09-08 2024-06-11 Paragonix Technologies, Inc. Tissue suspension adaptor

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
ZA200503977B (en) * 2002-12-20 2006-11-29 Unilever Plc Preparation of antifreeze protein
JP2004284983A (ja) * 2003-03-20 2004-10-14 National Institute Of Advanced Industrial & Technology 含水物中における物質の凍結濃縮を抑制する方法、生理活性物質の失活を抑制する方法、および成分が均質に拡散した凍結物又は凍結乾燥物を製造する方法
WO2013096659A1 (fr) * 2011-12-20 2013-06-27 Cook General Biotechnology Llc Procédés et compositions pour le stockage de cellules animales
KR101845715B1 (ko) * 2015-06-03 2018-04-05 (주)제노텍 동결방지제 조성물
US20220125042A1 (en) * 2017-05-17 2022-04-28 Universidade Nova De Lisboa Cryoprotectant and/or cryopreservant composition, methods and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030111638A1 (en) * 1995-03-30 2003-06-19 Gregory M. Fahy Methods of using ice-controlling molecules
US20030180704A1 (en) * 2002-03-19 2003-09-25 Brockbank Kelvin G.M. Ice-controlling molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016618A1 (fr) * 1998-09-21 2000-03-30 21St Century Medicine, Inc. Solutions de cryoprotection ameliorees

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030111638A1 (en) * 1995-03-30 2003-06-19 Gregory M. Fahy Methods of using ice-controlling molecules
US6773877B2 (en) * 1995-03-30 2004-08-10 Organ Recovery Systems, Inc. Methods of using ice-controlling molecules
US20030180704A1 (en) * 2002-03-19 2003-09-25 Brockbank Kelvin G.M. Ice-controlling molecules and uses thereof

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100476790B1 (ko) * 2002-09-13 2005-03-16 주식회사 제넨메드 세포 저장 용액과 이를 이용한 동물 세포의 동결 및 저장방법
US20050244692A1 (en) * 2002-11-05 2005-11-03 Hiroshi Egawa Fuel cell coolant composition
US20060145120A1 (en) * 2003-07-11 2006-07-06 Hiroshi Egawa Cooling liquid composition for fuel cell
US20080166615A1 (en) * 2003-07-11 2008-07-10 Hiroshi Egawa Cooling liquid composition for fuel cell
US8187763B2 (en) 2003-07-11 2012-05-29 Honda Motor Co., Ltd. Cooling liquid composition for fuel cell
US20070096054A1 (en) * 2003-10-01 2007-05-03 Hiroshi Egawa Coolant composition and methods of use thereof
US7258814B2 (en) 2003-10-01 2007-08-21 Shishiai-Kabushikigaisha Coolant composition and methods of use thereof
US20060237686A1 (en) * 2003-10-16 2006-10-26 Hiroshi Egawa Coolant composition
US20070007489A1 (en) * 2003-12-25 2007-01-11 Hiroshi Egawa Heat transfer medium composition
US20070075289A1 (en) * 2004-03-24 2007-04-05 Hiroshi Egawa Coolant composition for fuel cell
US20090142830A1 (en) * 2005-11-17 2009-06-04 Nippon Zenyaku Kogyo Co., Ltd. Aqueous Solution for Cell Preservation
US8460926B2 (en) 2005-11-17 2013-06-11 Nippon Zenyaku Kogyo Co., Ltd Aqueous solution for cell preservation
US8835158B2 (en) 2011-03-15 2014-09-16 Paragonix Technologics, Inc. Apparatus for oxygenation and perfusion of tissue for organ preservation
US9867368B2 (en) 2011-03-15 2018-01-16 Paragonix Technologies, Inc. System for hypothermic transport of samples
US11178866B2 (en) 2011-03-15 2021-11-23 Paragonix Technologies, Inc. System for hypothermic transport of samples
US11089775B2 (en) 2011-03-15 2021-08-17 Paragonix Technologies, Inc. System for hypothermic transport of samples
US9253976B2 (en) 2011-03-15 2016-02-09 Paragonix Technologies, Inc. Methods and devices for preserving tissues
US9426979B2 (en) 2011-03-15 2016-08-30 Paragonix Technologies, Inc. Apparatus for oxygenation and perfusion of tissue for organ preservation
US9936689B2 (en) 2011-03-15 2018-04-10 Paragonix Technologies, Inc. Methods and devices for preserving tissues
US8828710B2 (en) 2011-03-15 2014-09-09 Paragonix Technologies, Inc. System for hypothermic transport of samples
US9560846B2 (en) 2012-08-10 2017-02-07 Paragonix Technologies, Inc. System for hypothermic transport of biological samples
US9155297B2 (en) 2012-08-10 2015-10-13 Paragonix Technologies, Inc. Methods and systems for assessing the suitability of an organ for transplant
US8785116B2 (en) 2012-08-10 2014-07-22 Paragonix Technologies, Inc. Methods for evaluating the suitability of an organ for transplant
USD819223S1 (en) 2014-10-10 2018-05-29 Paragonix Technologies, Inc. Transporter for a tissue transport system
US11166452B2 (en) 2017-06-07 2021-11-09 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
US11659834B2 (en) 2017-06-07 2023-05-30 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
US11632951B2 (en) 2020-01-31 2023-04-25 Paragonix Technologies, Inc. Apparatus for tissue transport and preservation
USD1031028S1 (en) 2022-09-08 2024-06-11 Paragonix Technologies, Inc. Tissue suspension adaptor

Also Published As

Publication number Publication date
DE60104105T2 (de) 2005-07-07
EP1274302A1 (fr) 2003-01-15
ES2367352T3 (es) 2011-11-02
ATE270037T1 (de) 2004-07-15
EP1274302B1 (fr) 2004-06-30
AU2001255433A1 (en) 2001-10-30
JP2003530406A (ja) 2003-10-14
WO2001078505A1 (fr) 2001-10-25
DE60104105D1 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
US20020068360A1 (en) Cyclohexanediol cryoprotectant compounds
US6596531B2 (en) Two stage method for thawing cryopreserved cells
US8017311B2 (en) Method for treatment of cellular materials with sugars prior to preservation
US6395467B1 (en) Cryoprotectant solution containing dimethyl sulfoxide, an amide and ethylene glycol
US20020042131A1 (en) Cryopreservation method using cryoprotective composition of propanediol and a vehicle solution
US20050019917A1 (en) Methods and solutions for storing donor organs
JP4947948B2 (ja) 細胞保存液
JP2003520859A (ja) 器官および組織保存および低体温血液置換のためのシステム
Wowk How cryoprotectants work
JP3694730B2 (ja) 組織の冷却保存液
US20220079140A1 (en) Preservation of stem cells
Karow Chemical cryoprotection of metazoan cells
Jeevanandam et al. University of Wisconsin solution for human donor heart preservation: initial clinical experience
JP2020527601A (ja) 保存溶液
De Loecker et al. Metabolic changes in rat skin during preservation and storage in glycerol buffer at− 196° C
JPS6029471B2 (ja) 肝細胞の凍結方法
Bourne Clinical and experimental aspects of corneal cryopreservation
Armitagetage Feaibility of cornel vitrification
JP3877978B2 (ja) 細胞保存方法
Madden et al. An improved method of corneal cryopreservation
Rowley Cryopreservation of Hematopoietic Cells
Grishenko et al. Some aspects of embryo and sperm cryopreservation
Fuller et al. Cold shock: A common cellular injury?
Hirsh Mechanisms of cryoprotection of cells by extracellular cryoprotection

Legal Events

Date Code Title Description
AS Assignment

Owner name: ORGAN RECOVERY SYSTEMS, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROCKBANK, KELVIN G. M.;TAYLOR, MICHAEL J.;CAMPBELL, LIA HANSON;REEL/FRAME:012149/0688

Effective date: 20010412

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION